Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: Prediction of the equivalent AUC/MIC breakpoints and doses

International Journal of Antimicrobial Agents

Volumn 16, Issue 4, 2000, Pages 407-414

  Firsov, Alexander A ^a   Zinner, Stephen H ^b   Lubenko, Irene Yu ^a   Vostrov, Sergey N ^a  

^a Scientific and Technological Centre Lekbiotech   (Russian Federation)

^b MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Ciprofloxacin; Gemifloxacin; In vitro models; Pharmacodynamics

Indexed keywords

CIPROFLOXACIN; GEMIFLOXACIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; DRUG POTENCY; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SIMULATION; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NAPHTHYRIDINES; PREDICTIVE VALUE OF TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0033670107     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00226-0     Document Type: Article

References (40)

1. Quantitative analysis of antimicrobial effect kinetics in an intro dynamic model
2. A new approach to in vitro comparisons of antibiotics in dynamic models: Equivalent area under the curve-MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities
3. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model
4. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: Prediction of equiefficient doses and the breakpoints of the area under the Curve-MIC Ratio
5. Prevalence of resistance to erythromycin and in vitro activity of SB-265805 (LB20304a) against gram positive clinical isolates collected in Korea
6. SB-265805 (LB20304a): In vitro antibacterial activity and spectrum
7. Antibacterial activity of gemifloxacin and 14 comparator compounds against 895 gram negative clinical isolates
8. Comparative in vitro activity of grepafloxacin against fresh bacterial isolates from paediatric patients
9. A European Multicentre study of the comparative in vitro susceptability of gram-positive bacteria to levofloxacin
10. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
11. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci
12. Bactericidal activity of grepafloxacin against typical pathogens causing respiratory tract infections in comparison to macrolides and other oral antibiotics
13. In-vitro activity of trovafloxacin, a new fluoroquinolone, against resent clinical isolates
14. In vitro activity of moxifloxacin compared with other fluoroquinolone against bacterial strains from upper and lower respiratory tract infections in general practice
15. Antimicrobial activity of gatifloxacin, a newer 8-methoxy fluoroquimnolone, tested against over 23 000 recent clinical isolates from the SENTRY antimicrobial surveillance program
16. Activity of moxifloxacin and other fluoroquinolones against speciated staphylococci and potencial of staphylococci to develop resistance
17. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone
18. SB-265805 (LB 20304a): In vitro antibacterial activity against respiratory tract pathogens
19. Comparative in vitro activity of trovafloxacin against gram positive and -negative clinical isolates from Argentina
20. Comparative in vitro activity of moxifloxacin against respiratory tract patohogenes
21. In vitro activity of moxifloxacin against Gram-positive bacteria
22. In vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: A multicentre international study
23. In vitro activity of gatifloxacin against gram-positive aerobic bacteria, including Mycobacterium spp
24. In vitro susceptibility of the fluorquinolones trovafloxacin, ciprofloxacin, ofloxacin, sparfloxacin and 21 other antibiotics against consecutively obtained clinical isolates (1996-1997) from the university hospitals of Leipzig
25. In vitro activity of various antimicrobials against 194 unrelated clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates and stability of MIC values in 125 clonally related clinical MRSA
26. In vitro activity of Bay 12-8039, a novel 8-methoxyquinolone, against species representative of respiratory tract pathogens
27. Comparative in vitro activity of gatifloxacin, a new fluoroquinolone antimicrobial, against gram-positive bacteria
28. In vitro activity of moxifloxacin (Bay 12-8039) against Gram-positive clinical isolates
29. Comparative in vitro activity of moxifloxacin, trovafloxacin and quinupristin-dalfopristin against staphylococci
30. In vitro activity of grepafloxacin against H. influenzae, M. catarrhalis, S. pneumoniae, S. pyogenes and S. aureus
31. Comparative in vitro activity of grepafloxacin and comparators against E. coli, K. pneumoniae, P. aeruginosa, H. influenzae, M. catarralis, S, aureus and S. pneumoniae
32. Pharmacokinetics and tolerability of gemifloxacin after administration of single oral doses to healthy volunteers
33. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers
34. Pharmacokinetics and bioavailability of ciprofloxacin
35. Pharmacokinetics of ciprofloxacin after oral and parenteral administration
36. The comparative pharmacokinetics of five quinolones
37. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model
38. Inter-and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept
39. Antipneumococcal activity of SB-265805 (LB20304a), a new broad-spectrum quinolone, compared with nine compounds by MIC